Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fspecialisation%2Foncology%2Fasco-gu-2022%2Ffirst-line-avelumab-shows-clinical-activity-in-advanced-urothelial-carcinoma%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=3.93.74.25&categories=Conference+Report+Article%7CUrothelial+Carcinoma%7CASCO+GU+2022%7COncology%7CGenitourinary+Cancer%7CUrology&conference=ASCO+GU+2022): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
First-line avelumab shows clinical activity in advanced urothelial carcinoma - Medical Conferences

Home > Oncology > ASCO GU 2022 > Urothelial Carcinoma > First-line avelumab shows clinical activity in advanced urothelial carcinoma

First-line avelumab shows clinical activity in advanced urothelial carcinoma

Presented By
Dr Roberto Iacovelli, Catholic University of Rome, Italy

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
Trial
Phase 2, ARIES
Results from the phase 2 ARIES trial showed that avelumab was clinically active and safe in cisplatin-ineligible patients with advanced urothelial cancer.

About 50% of patients with advanced urothelial cancer are considered cisplatin-ineligible [1]. Avelumab is approved as maintenance therapy after platinum-based first-line therapy for patients with advanced urothelial cancer based on the phase 3 Javelin Bladder 100 study (NCT02603432), which showed significant overall survival (OS) improvement [2].

The phase 2 ARIES trial (NCT03891238) explored the activity of avelumab as first-line therapy in cisplatin-unfit patients with advanced urothelial cancer and positive PD-L1 expression. Enrolled were 198 patients with advanced urothelial cancer who were cisplatin-unfit. Of these participants, 71 were PD-L1-positive (CPS ≥5%) and treated with avelumab until progression, unacceptable toxicity, or withdrawal, whichever occurred first. The primary endpoint was 1-year OS. Dr Roberto Iacovelli (Catholic University of Rome, Italy) presented the results [3].

After a median follow-up of 9.0 months, 13 (19%) patients were still on treatment. The median OS was 10.0 months, and 40.8% of patients were alive at 1 year. Median OS in patients with CPS ≥10% (n=56) was 13.0 months, compared with 7.0 months for patients with CPS <10% (P=0.09; see Figure). Median PFS was 2.0 months, irrespective of CPS. The ORR for all patients was 22.5% (1 complete response, 15 partial responses). The clinical benefit rate was 43.6%.

Figure: Overall survival in ARIES [3]



Avelumab showed a favourable safety profile with 30 (42%) patients reporting a grade ≥3 adverse event.

Based on these results, Dr Iacovelli concluded that first-line avelumab is clinically active and safe in patients with advanced urothelial cancer who are unfit for cisplatin-based therapy.

  1. Cathomas R, et al. Hematol Oncol Clin North Am. 2015;2:329–340.

  2. Powles T, et al. N Engl J Med 2020;383:1218–1230.

  3. Iacovelli R, et al. First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial. Abstract 439, ASCO GU 2022, 17–19 February.

 

Copyright ©2022 Medicom Medical Publishers



Posted on